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Sir,
Early initiation of combination antiretroviral therapy (cART) in
AIDS presenters reduces mortality,1 but seems to worsen survi-
val in cryptococcal meningitis, probably because of immune
reconstitution inflammatory syndrome (IRIS), with fatal cerebral
complications.2,3 Timing of cART initiation is not clearly defined,
ranging from 2 to 10 weeks.4 Strategies aiming at reducing the
risk of IRIS are lacking.
We report a case of pulmonary and mediastinal lymph node
cryptococcosis occurring late after immune reconstitution and
fluconazole prophylaxis discontinuation in a patient with pre-
vious AIDS-presenting disseminated/meningeal cryptococcosis.
A Pakistani man in his mid-forties presented with AIDS and dis-
seminated/meningeal cryptococcosis (CD4 count 16 cells/mm3,
plasma HIV-1 RNA 191100 copies/mL and blood and CSF cultures
positive for Cryptococcus neoformans). He was treated with a stan-
dard amphotericin B course, followed by secondary fluconazole
prophylaxis; cART was introduced 1 month later with co-formulated
zidovudine/lamivudine and lopinavir/ritonavir, achieving virological
suppression and immune restoration (Figure 1). The nucleoside
backbone was switched to tenofovir/emtricitabine after
1 month, because of bone marrow toxicity (haemoglobin
8.3 g/dL, white blood cells 1910/mm3 and neutrophils 390/mm3).
Lumbar puncture performed at baseline and after 3 months
showed a decrease in HIV-1 RNA in the CSF, although the
CSF/plasma viral load ratio did not decrease accordingly
(2867/191100 copies/mL¼0.02 at baseline versus 123/
314 copies/mL¼0.39 at month 3). In the absence of new clini-
cal symptoms, cryptococcal soluble antigen titre in the CSF
increased from 1:512 at baseline to 1:2048 at month 3, but
culture was negative; no other neurotropic viruses (herpes
viruses 1 and 2, varicella-zoster virus, cytomegalovirus,
Epstein–Barr virus or JC virus) were detected by PCR.
A viral blip at month 5 (HIV-1 RNA 1170 copies/mL) was not
confirmed (HIV-1 RNA ,50 copies/mL after 2 weeks); lopinavir/
ritonavir trough concentrations were adequate (5931 ng/dL/
306 ng/dL).
Fluconazole prophylaxis was stopped after 8 months of cART
and CD4 count .200 cells/mm3, according to guidelines.
Nine months later, the patient presented with cough, malaise,
weight loss, anorexia and severe dysphagia. Endoscopy revealed
extrinsic oesophageal compression. A whole-body CT scan
showed enlargement of mediastinal lymph nodes and bilateral
apical pulmonary solid infiltrations. Sputum smears were negative
for acid-fast bacilli (even by PCR) and other microbes; T cell
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Figure 1. Viral load (filled triangles) and CD4 T cell count (open squares) variation during patient treatment history. Grey-shaded boxes represent
serum and CSF cryptococcal soluble antigen titres over time, expressed in weeks (W) after the start of cART. T0 corresponds to the first
presentation, 1 month earlier.
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interferon-g release assay (Quantiferonw) was negative. Trans-
bronchial fine-needle aspirate of the mediastinal lymph nodes
and CT-guided fine-needle pulmonary aspirate, after routine
Papanicolaou and May–Gru¨nwald–Giemsa staining, surprisingly
revealed the presence of yeast spores whose shapes were sugges-
tive of cryptococci. C. neoformans was not detected in the CSF at
ink coloration on a new lumbar puncture; the cryptococcal
soluble antigen was negative in the CSF, although slightly positive
(1:32) in the serum. CSF HIV-1 RNA was 585 copies/mL. Pending
culture results, despite initial spontaneous clinical improvement
without any added treatment (including steroids), fluconazole
treatment of pulmonary cryptococcosis was started at 400 mg,
and progressive clinical improvement was observed. Eventually,
cultures of both fine-needle aspirate and CSF were negative.
This case raises several clinical management-related issues.
Should it be considered relapse or late IRIS? Should fluconazole
prophylaxis have been maintained for longer? Could a cART with
a higher penetration coefficient have reduced the risk of persistent
viral replication in the CSF, which may have contributed to the sys-
temic persistence of non-viable cryptococcal antigen?
Risk factors for cryptococcal relapse include a CD4 count of
,100 cells/mm3, receipt of antifungal therapy for ,3 months
during the previous 6 months and serum cryptococcal antigen
titre ≥1:512.5 Unusual clinical presentation of cryptococcosis
suggests a form of late IRIS; different localization from previous
meningeal infection, culture-negative cryptococcal antigenae-
mia (reflecting a response towards non-viable pathogens) and
self-resolving trend after abrupt clinical presentation are all
factors associated with immune restoration disease.6 Our case
fulfills the criteria of a recent case definition for paradoxical cryp-
tococcal IRIS,7 except for the timing of occurrence (.12 months
after cART initiation). Nevertheless, IRIS occurring as late as
27 months has been described in the context of cryptococcal
disease.8
The risk of cryptococcal relapse after discontinuation of sec-
ondary prophylaxis is low, provided patients have completed
primary therapy and have been receiving cART with a sustained
CD4 count .100 cells/mm3 and undetectable viral load.9,10 In
this case, it could not be excluded that longer antifungal drug
exposure after the first cryptococcal disease might have
reduced the burden of non-viable cryptococcal antigen, and
thus the risk of late IRIS.
Opportunistic meningeal infections can enhance HIV replica-
tion in vitro.11 The rise in CSF HIV-1 RNA observed during menin-
geal cryptococcosis has been recently correlated with
interleukin-10, suggesting that the proinflammatory response
needed to more efficiently control cryptococcal infection could
result in sustained HIV replication in the CSF.12 In this context
a cART with a higher penetration coefficient13 could have
resulted in better CSF viral control.
This case underlines the diagnostic challenge of late-
presenting cryptococcal IRIS. The aggressive diagnostic
work-up led to the discovery of an unexpected pathological
finding, revealing a treatable condition. Lacking predictive
factors, clinicians should be aware of unusual cryptococcal
presentations.
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